LNAI 8-K
Lunai Bioworks Inc. (LNAI)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or
15(d) of the
Securities ExchangeAct of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices)
+1
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of theAct:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On October 15, 2025, Lunai Bioworks (the “Company”) received a Notice from the NASDAQ Stock Market that the Company has regained compliance with Listing Rule 5550(a)(2). On April 14, 2025, the NASDAQ staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous thirty (30) consecutive business days as required by the Listing Rules of the NASDAQ Stock Market. Since then, the staff of NASDAQ has determined that for the last eleven (11) consecutive business days from September 30, 2025 to October 14, 2025, the closing bid price of the Company’s common stock has been at $1.00 per share or greater.
Item 9.01 Financial Statements and Exhibits.
A Press Release announcing compliance with the Listing Rule was published by the Company on October 16, 2025, a copy of which is filed herewith as Exhibit 99.1
Exhibit Index
| Exhibit No. | Description |
| 99.1 | Press Release Announcing Compliance with the List Requirements dated October 16, 2025. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LUNAI BIOWORKS, INC. | ||
| By: | /s/ David Weinstein | |
| Name: David Weinstein | ||
| Title: Chief Executive Officer | ||
| Date: October 16, 2025 | ||
EXHIBIT 99.1
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
LOS ANGELES, October 16, 2025: Lunai Bioworks, Inc. (Nasdaq: LNAI), today announced that it has regained compliance with Nasdaq’s minimum bid price requirement.
On April 14, 2025, Nasdaq Staff notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Listing Rule 5550(a)(2). However, Staff has since determined that for the 11 consecutive business days from September 30, 2025 through October 14, 2025, the closing bid price of Lunai Bioworks’ common stock was at or above $1.00 per share. As a result, the Company has now regained compliance with the rule and remains eligible for continued listing on The Nasdaq Capital Market.
“This compliance milestone reflects our commitment to strategic execution and shareholder value during a transformative period for Lunai Bioworks,” said David Weinstein, Chief Executive Officer. “We remain focused on advancing our AI-powered platform and delivering long-term impact across drug discovery and biodefense.”
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Media Contact:
David Weinstein
Chief Executive Officer
305-918-1980
[email protected]
http://www.lunaibioworks.com/